Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Donations

- PMLiVE

Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals

Arena is a clinical stage company developing innovative potential therapies for immuno-inflammatory diseases

- PMLiVE

Pfizer begins phase 2/3 study of oral COVID-19 treatment in paediatric patients

The phase 2/3 trial involves around 140 patients under the age of 18

- PMLiVE

Pfizer’s Lorviqua receives EC approval for treatment of advanced lung cancer

The approval is based on the phase 3 CROWN trial comparing Lorviqua with Xalkori

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine

The clinical trial involves adults aged 18 to 55 who received an Omicron-based vaccine candidate as part of a two-dose primary series, as well as a booster

- PMLiVE

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

The FDA based its approval on results from a clinical trial programme involving over 1,600 patients

- PMLiVE

BMS and 2seventy bio move away from CAR-T programme

The two companies will focus their efforts on furthering the growing success of BMS’ therapy Abecma

- PMLiVE

Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics

Acuitas’ LNP technology is already used in the Pfizer/BioNTech COVID-19 vaccine, Comirnaty

- PMLiVE

Pfizer/BioNTech confirm new global collaboration to develop first mRNA-based shingles vaccine

The companies plan to begin clinical trials of the new vaccine in the second half of 2022

The Ongoing Evaluation of Medical Affairs

Eddie Power, Vice President of North America Medical Affairs, Hospital Business at Pfizer, discusses a range of topics, including the effects of COVID-19 on the way Medical Affairs teams work...

Impetus Digital

- PMLiVE

FDA approves Amgen’s Otezla for all patients with plaque psoriasis

The FDA has expanded use of Otezla to adults with mild to moderate plaque psoriasis, making it the first oral treatment for the skin condition, regardless of severity

- PMLiVE

Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio

The cash deal includes Arena’s lead candidate, etrasimod, which is currently in trials for ulcerative colitis, Crohn’s disease and atopic dermatitis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links